A New Millennium For Takeda Oncology
This article was originally published in PharmAsia News
Executive Summary
After spending $8.8 billion in 2008 to acquire Millennium, Takeda is changing the identity of its oncology unit to present a more unified corporate front and reinforce its already substantial commitment to the sector.